article thumbnail

Optimizing participation in the OECD PaRIS Project: Lessons learned in Saskatchewan [Survey research or cross-sectional study]

Annals of Family Medicine

Setting: Primary care clinics across Saskatchewan. Descriptive and inferential statistics were undertaken. Recruitment success was built on integrating PCPs, as co-researchers, into the process.

article thumbnail

Why I don’t do “weight loss” as a primary care physician

Vida Family Medicine

From specialized obesity clinics to online services offering quick prescriptions, the options can feel overwhelming. While losing weight is often suggested to lower the risk of chronic conditions like diabetes, high blood pressure, or heart disease, the risk of prescribing weight loss is overlooked.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Deprescribing Super Special III: Constance Fung, Emily McDonald, Amy Linsky, and Michelle Odden

GeriPal

Join us as we dive deeper into these studies and discuss the implications for clinical practice and patient care. And there’s so much work on, you know, you’ve got to take these medicines, you got to prevent this treat, that there isn’t that same sort of clinical momentum towards deprescribing. Ethical and practical.

article thumbnail

Hearing Loss in Geriatrics and Palliative Care: A Podcast with Nick Reed and Meg Wallhagen

GeriPal

Was there any mention about the impact that hearing loss has in communication or what we should do about it in clinical practice? Lastly, I also just want to give a shout out to the last article above which also includes this lovely checklist of methods to address hearing loss in clinical encounters. I’m guessing not. Transcript.

IT 102
article thumbnail

Rethinking Opioid Conversions: Mary Lynn McPherson and Drew Rosielle

GeriPal

It depends on the clinical situation. But I think people would have an embolic event if you gave them a flipping range. But we still, regardless of how you do this calculation have to temper it with clinical judgment. Mary Lynn: I’m willing to bet that you temper that calculation with your clinical judgment though.

IT 139
article thumbnail

Psychedelics – reasons for caution: Stacy Fischer, Brian Anderson, Theora Cimino

GeriPal

FDA is considering approval, shifting away from Schedule I restrictions, paving the way for use in clinical practice. Potential use in palliative care , chronic pain , and for mood disorders is tantalizing. And some people in studies and just in clinical use have found that to be helpful, including for patients with serious illness.

article thumbnail

The MAHA Assessment’s Implications: Drugs (Part One)

FDA Law Blog

Indications for chronic diseases do not generally reflect the length of the clinical trial; FDA determines that clinical trials supporting such approvals are of sufficient duration and makes an approval determination.